Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine

Vaccine-mediated immune thrombocytopenia, although previously reported, is considered exceedingly rare. The probability of the incidence of profound thrombocytopenia following the COVID-19 mRNA-based vaccine has been less elucidated. We present the case of an 81-year-old female patient who became pr...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-12, Vol.14 (12), p.e32873
Main Authors: Breetz, Katherine A, Cooper, Daniel P, Reeves, Shane A, Lodhi, Samra Haroon, Ahmed, Taha
Format: Article
Language:English
Subjects:
Asymptomatic
Blood
Blood platelets
Case reports
Coronaviruses
COVID-19 vaccines
Dehydrogenases
Drug dosages
Emergency Medicine
Infections
Influenza
Internal Medicine
Laboratories
Measles
Medical Education
Mumps
Patients
Rheumatoid arthritis
Rubella
Steroids
Thrombocytopenia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccine-mediated immune thrombocytopenia, although previously reported, is considered exceedingly rare. The probability of the incidence of profound thrombocytopenia following the COVID-19 mRNA-based vaccine has been less elucidated. We present the case of an 81-year-old female patient who became profoundly thrombocytopenic with bleeding manifestations six days after the Moderna mRNA-1273 vaccine administration. Fortunately, she exhibited platelet count recovery after treatment with intravenous immunoglobulins and steroid therapy. Furthermore, we show that the inherent risk of COVID-19 infection leading to thrombocytopenia significantly outweighs the vaccine's risk.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.32873